Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC

Authors

PG Lopez
RE Sanborn, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

3-29-2023

Keywords

oregon; chiles

Abstract

ELCC Conference; March 29; Copenhagen Denmark. 2023: 30.

Clinical Institute

Cancer

Department

Oncology

Comments

Lopez PG, Girard N, Cho BC, Sabari J, Spira A, Sanborn RE, Goto K, Yang JC, Curtin J, Lyu X, He A, Penton J, Edwards J, Massin GL, Xia K, Chioda M, Thayu M, Knoblauch RE, Mahadevia P, Leighl N

Recommended Citation

Lopez, PG; Sanborn, RE; and See full list of authors in comments, "Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC" (2023). Articles, Abstracts, and Reports. 7964.
https://digitalcommons.providence.org/publications/7964